... metastases and treatment response to transarterial embolization (TAE) in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Methods: Circulating Tregs, defined as the CD4 + CD25 + CD127 low/− population, were examined by flow cytometry in peripheral blood mononuclear cells from patients...

... rates were 62% versus 63% ( p = 0.98), and PD rates were 21% versus 37% ( p = 0.38). Chemotherapy Gastroenteropancreatic neuroendocrine tumors Metastases FOLFOX Insulinomas For metastatic disease, systemic treatment options supported by randomized trials mainly include...

... Gastroenteropancreatic neuroendocrine tumors Pancreatic neoplasms Streptozocin Everolimus Temozolomide National Institutes of Health (NIH) 10.13039/100000002 Neuroendocrine tumors that originate from the pancreatic islet cells represent a rare and heterogeneous group of tumors with diverse...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Stage IV Metastases Gastroenteropancreatic neuroendocrine tumors Lung Survival Brain Carcinoid Neuroendocrine neoplasms (NEN) constitute a heterogeneous group...

... gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The aim of the study was to validate the NETest®, a blood molecular genomic analysis, for predicting the course of disease in individual patients compared to chromogranin A (CgA). NETest® score (normal ≤20%) and CgA level (normal <100 µg/L) were measured in 152...

... and 739% for patients with regression; and 714 and 603% for patients with progressive disease (PD). Gastroenteropancreatic neuroendocrine tumors Chromogranin A Biomarkers A general characteristic of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) is the expression of chromogranin...

... Gastroenteropancreatic neuroendocrine tumors Liver metastases The incidence of newly discovered pancreatic neuroendocrine tumors (pan-NENs) has increased over the years, mainly due to the extensive use of cross-sectional imaging. Although these tumors account for only 1–5% of all pancreatic tumors [ 1-4 ], pan...

..., instructions or products referred to in the content or advertisements. 5-Hydroxyindoleacetic acid Carcinoid heart disease Carcinoid syndrome Gastroenteropancreatic neuroendocrine tumors Imaging Serotonin Midgut neuroendocrine tumors (MNETs) represent 26% of diagnosed neuroendocrine neoplasms...

... mTOR inhibition Everolimus Gastroenteropancreatic neuroendocrine tumors Signaling 4E-BP1 LCC-18 cell line The rare tumor entity of gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) shows heterogeneity in its clinical behavior and lacks proper therapeutic options. A small...

...Roxanne C.S. van Adrichem; Wouter W. de Herder; Kimberly Kamp; Michael P. Brugts; Ronald R. de Krijger; Diana M. Sprij-Mooij; Steven W.J. Lamberts; Peter M. van Koetsveld; Joseph A.M.J.L. Janssen; Leo J. Hofland Background: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) express insulin...

... Oxaliplatin Pancreatic neuroendocrine tumors Gastroenteropancreatic neuroendocrine tumors Neuroendocrine tumors (NETs) usually present as advanced, nonfunctioning and low/ intermediate grade of malignancy, and only in a minority of cases as high grade [ 1 ]. Though many NETs are clinically silent...

... ) immunohistochemistry (IHC) has additional value compared to somatostatin receptor scintigraphy (SRS) uptake using OctreoScan® in predicting response to peptide receptor radiotherapy using 177 Lu-octreotate (PRRT) in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The aims of this study were: (1...

... or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Gastroenteropancreatic neuroendocrine tumors Molecular imaging...

...Wen-Chi Chou; Yu-Shin Hung; Jun-Te Hsu; Jen-Shi Chen; Chang-Hsien Lu; Tsann-Long Hwang; Kun-Ming Rau; Kun-Yun Yeh; Tse-Ching Chen; Chien-Feng Sun Purpose: To evaluate the significance of plasma chromogranin A (CgA) levels in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET...

...Esther I. van Vliet; Jaap J.M. Teunissen; Boen L.R. Kam; Marion de Jong; Eric P. Krenning; Dik J. Kwekkeboom The primary treatment of gastroenteropancreatic neuroendocrine tumors (GEPNETs) is surgery with curative intent or debulking of the tumor mass. In case of metastatic disease, cytoreductive...

...I. Georgieva; D. Koychev; Y. Wang; J. Holstein; W. Hopfenmüller; M. Zeitz; P. Grabowski Background: Therapeutic approaches to gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are still not satisfactory. A new direction in treatment options could be the novel aurora kinase inhibitor ZM447439...

...Patricia Grabowski; Sonja Griβ; Christian N. Arnold; Dieter Hörsch; Rüdiger Göke; Rudolf Arnold; Berhard Heine; Harald Stein; Martin Zeitz; Hans Scherübl Gastroenteropancreatic neuroendocrine tumors represent a heterogeneous tumor entity. The growth pattern ranges from very slowly to fast growing...

... of benign and malignant diseases, including eye and CNS hemangioblastomas, renal cell carcinoma and pheochromocytoma are the major components. Gastroenteropancreatic neuroendocrine tumors are also listed among the typical complications, although these occur seldom. Virtually all such tumors are pancreatic...